Buy Rating for Apogee Therapeutics: Promising Prospects for Dupixent and APG808 in COPD Market
Apogee Therapeutics Welcomes Dr. Bollinger to Board
Express News | Apogee Therapeutics Expands Board of Directors With the Appointment of Lisa Bollinger, Md
Here's Why We're Not Too Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Situation
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic
Apogee Therapeutics Starts Phase 2 Trial for Atopic Dermatitis Drug
Express News | Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of Apg777, a Novel Subcutaneous Half-Life Extended Anti-Il-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
Buy Rating on Apogee Therapeutics: Promising Drug Developments and Strong Financials
Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics' Q1 Net Loss Widens
Apogee Therapeutics (APGE) reported a Q1 net loss Monday of $32.1 million, widening from its $12.5 million net loss a year earlier. Analysts polled by Capital IQ expected a net loss of $28.9 million.
Apogee Therapeutics | 10-Q: Quarterly report
Apogee Therapeutics Advances in Clinical Trials for Promising Treatments in Inflammatory Diseases, and Reported Net Loss of $(32.1)M, Held $816.2M in Cash
Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (C
Express News | Apogee Therapeutics Inc: $816 Mln Cash, Cash Equivalents and Marketable Securities With Runway Into 2028
Express News | Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
Express News | Apogee Therapeutics Shares Are Trading Higher After B of A Securities Initiated Coverage on the Stock With a Buy Rating
Express News | Apogee Therapeutics Inc : BofA Global Research Initiates Coverage With Buy Rating; Price Objective $80
Apogee Therapeutics Initiated at Buy by B of A Securities
Apogee Therapeutics Initiated at Buy by B of A Securities
B of A Securities Initiates Coverage On Apogee Therapeutics With Buy Rating, Announces Price Target of $80
B of A Securities analyst Geoff Meacham initiates coverage on Apogee Therapeutics with a Buy rating and announces Price Target of $80.
Apogee Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 51.17% B of A Securities → $80 Initiates Coverage On → Buy 03/06/2024 41.72% Jefferies $37 → $7
No Data